The main issue I have with what you are implying is that somehow medical professionals are corrupt if they are paid by the company who owns the drug. I'm sorry to have to reveal to you that EVERY SINGLE drug you have ever prescribed to a patient was approved based on studies paid for by the drug owners. And we are talking on average of $1B per drug indication. So plenty of incentive for corruption even with regulatory oversight.
Yes, you may claim you didn't use the word 'corrupt' but that is your implicit accusation. A huge slur on your own profession. Really poor form, IMO.
Even the FDA brings in panels from industry to help make their regulatory decisions. It's impossible to do independent studies and approvals as all the experts are in the industry and they all interlink with each other. These kids are very fortunate that Mesoblast is even funding such work given big Pharma wouldn't touch this due to it being a rare disease. And by implication, to suggest Mesoblast is corrupt by funding these corrupt medical professionals is an insult, personally to me, as a shareholder.
If you have an issue with the science, go for it. But also treat it for what it is - a 2 person case study. An appropriate start for a very rare disease which has had an apparent spike due to C19. You won't see any statistically powered RCT's for this condition probably this decade.
MSB Price at posting:
$2.65 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)